Control of MHC restriction by TCR V(α) CDR1 and CDR2

Science

Volumn 273, Issue 5277, 1996, Pages 963-966

  Sim, Bee Cheng ^a   Zerva, Loukia ^b   Greene, Mark I ^b   Gascoigne, Nicholas R J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ARTICLE; GENE EXPRESSION REGULATION; GENE MUTATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0029791413     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5277.963     Document Type: Article

References (43)

1. S. C. Jameson, K. A. Hogquist, M. J. Bevan, Annu. Rev. Immunol. 13, 93 (1995).
2. H. S. Teh et al., Nature 335, 229 (1988); W. C. Sha et al., ibid., p. 271.
3. H. S. Teh et al., Nature 335, 229 (1988); W. C. Sha et al., ibid., p. 271.
4. L. J. Berg et al., Cell 58, 1035 (1989); J. Kaye et al., Nature 341, 746 (1989).
5. L. J. Berg et al., Cell 58, 1035 (1989); J. Kaye et al., Nature 341, 746 (1989).
6. S. C. Jameson, J. Kaye, N. R. J. Gascoigne, J. Immunol. 145, 1324 (1990).
7. S. C. Jameson et al., ibid. 147, 3185 (1991).
8. H. Pircher et al., Eur. J. Immunol. 22, 399 (1992).
9. S. J. Saouaf et al., Transgenics 1, 185 (1994).
10. Y. Utsunomiya et al., J. Immunol. 143, 2602 (1989).
11. K. Tomonari, Immunogenetics 35, 291 (1992); H. DerSimonian, H. Band, M. B. Brenner, J. Exp. Med. 174, 639 (1991).
12. K. Tomonari, Immunogenetics 35, 291 (1992); H. DerSimonian, H. Band, M. B. Brenner, J. Exp. Med. 174, 639 (1991).
13. B. A. Fields et al., Science 270, 1821 (1995).
14. M. M. Davis and P. J. Bjorkman, Nature 334, 395 (1988); C. Chothia, D. R. Bothwell, A. M. Lesk, EMBO J. 7, 3745 (1988); J.-M. Claverie, A. Prochnicka-Chalufour, L. Bougueleret, Immunol. Today 10, 10 (1989).
15. M. M. Davis and P. J. Bjorkman, Nature 334, 395 (1988); C. Chothia, D. R. Bothwell, A. M. Lesk, EMBO J. 7, 3745 (1988); J.-M. Claverie, A. Prochnicka-Chalufour, L. Bougueleret, Immunol. Today 10, 10 (1989).
16. M. M. Davis and P. J. Bjorkman, Nature 334, 395 (1988); C. Chothia, D. R. Bothwell, A. M. Lesk, EMBO J. 7, 3745 (1988); J.-M. Claverie, A. Prochnicka-Chalufour, L. Bougueleret, Immunol. Today 10, 10 (1989).
17. B.-C. Sim and N. R. J. Gascoigne, data not shown.
18. B. Arden, S. P. Clark, D. Kabelitz, T. W. Mak, Immunogenetics 42, 501 (1995).
19. Mutations are designated by the wild-type residue, followed by its position, and the mutant residue. Abbreviations for the amino acid residues are as follows: F, Phe; P, Pro; S, Ser; and W, Trp.
20. α3.2 (AV3S2) (8). The AV3S5J31 genomic clone was mutated by polymerase chain reaction overlap extension [S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, Gene 77, 51 (1989)] and cloned into a genomic α-chain vector [V. Kouskoff, K. Signorelli, C. Benoist, D. Mathis, J. Immunol. Methods 180, 273 (1995)]. Transgenic mice were generated at The Scripps Research Institute (TSRI) with FVB oocytes and backcrossed to C57BL/6J (B6) mice. All animals were treated in accordance with TSRI institutional guidelines.
21. α3.2 (AV3S2) (8). The AV3S5J31 genomic clone was mutated by polymerase chain reaction overlap extension [S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, Gene 77, 51 (1989)] and cloned into a genomic α-chain vector [V. Kouskoff, K. Signorelli, C. Benoist, D. Mathis, J. Immunol. Methods 180, 273 (1995)]. Transgenic mice were generated at The Scripps Research Institute (TSRI) with FVB oocytes and backcrossed to C57BL/6J (B6) mice. All animals were treated in accordance with TSRI institutional guidelines.
22. α3.2 (AV3S2) (8). The AV3S5J31 genomic clone was mutated by polymerase chain reaction overlap extension [S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, Gene 77, 51 (1989)] and cloned into a genomic α-chain vector [V. Kouskoff, K. Signorelli, C. Benoist, D. Mathis, J. Immunol. Methods 180, 273 (1995)]. Transgenic mice were generated at The Scripps Research Institute (TSRI) with FVB oocytes and backcrossed to C57BL/6J (B6) mice. All animals were treated in accordance with TSRI institutional guidelines.
23. α3.2 (AV3S2) (8). The AV3S5J31 genomic clone was mutated by polymerase chain reaction overlap extension [S. N. Ho, H. D. Hunt, R. M. Horton, J. K. Pullen, L. R. Pease, Gene 77, 51 (1989)] and cloned into a genomic α-chain vector [V. Kouskoff, K. Signorelli, C. Benoist, D. Mathis, J. Immunol. Methods 180, 273 (1995)]. Transgenic mice were generated at The Scripps Research Institute (TSRI) with FVB oocytes and backcrossed to C57BL/6J (B6) mice. All animals were treated in accordance with TSRI institutional guidelines.
24. α3.1 (7) was used with goat anti-rabbit (H+L)-FITC. Red613-conjugated anti-CD4 (H129.19), anti-CD8α (53-6.7), and anti-Thy 1.2-PE (30-H12) were obtained from Gibco BRL (Grand Island, NY).
25. b.
26. 27 in the CDR1 region.
27. +.
28. α3.1 m (line 7): 10.4, 11.2, and 23.4%; CDR1m (line 8): 26.4, 17.4, and 29.5%; and CDR2m (line 44): 24.9, 16.4, and 31.1%.
29. d (SF1-1.1 ) to distinguish donor cells.
30. β3-8, 10, 11, and 13, but did not see any significant differences.
31. F. R. Carbone, S. J. Sterry, J. Butler, S. Rodda, M. W. Moore, Int. Immunol. 4, 861 (1992); L. J. Berg, B. Fazekas de St. Groth, A. M. Pullen, M. M. Davis, Nature 340, 559 (1989).
32. F. R. Carbone, S. J. Sterry, J. Butler, S. Rodda, M. W. Moore, Int. Immunol. 4, 861 (1992); L. J. Berg, B. Fazekas de St. Groth, A. M. Pullen, M. M. Davis, Nature 340, 559 (1989).
33. β, transgenic mice were bred at TSRI.
34. C. A. Janeway Jr. and K. Bottomly, Semin, Immunol. 8, 109 (1996).
35. J. H. Brown et al., Nature 332, 845 (1988): J. H. Brown et al., ibid. 364, 33 (1993).
36. J. H. Brown et al., Nature 332, 845 (1988): J. H. Brown et al., ibid. 364, 33 (1993).
37. U. Dianzani, A. Shaw, B. K. Al-Ramadi, R. T. Kubo, C. A. Janeway Jr., J. Immunol. 148, 678 (1991); I. F. Luescher et al., Nature 373, 353 (1995).
38. U. Dianzani, A. Shaw, B. K. Al-Ramadi, R. T. Kubo, C. A. Janeway Jr., J. Immunol. 148, 678 (1991); I. F. Luescher et al., Nature 373, 353 (1995).
39. E. Jouvin-Marche et al., EMBOJ. 9, 2141 (1990); N. R. J. Gascoigne, in J Cell Receptors, J. I. Bell, M. J. Owen, E. Simpson, Eds. (Oxford Univ. Press, Oxford, 1995), p. 288.
40. E. Jouvin-Marche et al., EMBOJ. 9, 2141 (1990); N. R. J. Gascoigne, in J Cell Receptors, J. I. Bell, M. J. Owen, E. Simpson, Eds. (Oxford Univ. Press, Oxford, 1995), p. 288.
41. J. H. Russell et al., J. Immunol. 144, 3318 (1990); H. von Boehmer, J. Kirberg, B. Rocha, J. Exp. Med. 174, 1001 (1991).
42. J. H. Russell et al., J. Immunol. 144, 3318 (1990); H. von Boehmer, J. Kirberg, B. Rocha, J. Exp. Med. 174, 1001 (1991).
43. β5 transgenics by M. Moore and C. Surh (Genentech and TSRI). Antibody RL172 was provided by H. R. MacDonald (Ludwig Institute, Lausanne). We are grateful to D. Lo and S. Jameson for critical review of the manuscript. This is publication number 9877-IMM from TSRI.